Status:
COMPLETED
Study of the Electrocardiographic Effects of TA-8995
Lead Sponsor:
Xention Ltd
Conditions:
Dyslipidaemia
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
A study in healthy males and females to see if a high single dose of TA-8995 has an effect on the ECG QTcF interval.
Eligibility Criteria
Inclusion
- Healthy male or females of non-child bearing potential
Exclusion
- Receiving any other drug therapy
- Clinically significant medical history
- Abnormal ECGs or vital signs
Key Trial Info
Start Date :
August 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2014
Estimated Enrollment :
136 Patients enrolled
Trial Details
Trial ID
NCT02241759
Start Date
August 1 2014
End Date
December 1 2014
Last Update
February 16 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Covance Clinical Research Unit Ltd
Leeds, United Kingdom, LS2 9LH